The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Curative and palliative radiation in patients with NSCLC with cachexia
Puneeth Iyengar, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes cancer cachexia (CC), which is prevalent in a third of patients with advanced non-small cell lung cancer (NSCLC). Patients with CC lose their appetite, leading to reduced adipose and muscle mass, significantly reducing survival rate. CC patient prognosis is not improved by curative or palliative radiation, meaning treatment of CC patients must include targeted action to reduce fat and muscle loss alongside tumor-directed therapy. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
